Overview

• Resistance among monitored antibiotics rose by more than 40% between 2018 and 2023, according to the new global analysis.
• The highest burdens were recorded in Southeast Asia and the Eastern Mediterranean, where about one in three infections did not respond to treatment, while Africa saw roughly one in five.
• Over 40% of Escherichia coli and more than 55% of Klebsiella pneumoniae infections are resistant to third‑generation cephalosporins, and rising carbapenem resistance is pushing reliance on costly last‑line drugs often unavailable in low‑ and middle‑income countries.
• GLASS participation expanded from 25 countries in 2016 to 104, yet 48% of countries still did not report data and many submissions lack robustness, with WHO targeting universal high‑quality national reporting by 2030.
• WHO cites more than 1 million deaths directly attributable to antimicrobial resistance each year and around 5 million associated deaths.